Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Gator who wrote (32229)	1/11/1999 1:25:00 PM
From: Fuzzy	Respond to of 34592

Good call Gator, have you checked out TEVE's news today? Related QuotesCMCSA TEVE 59 3/4 0.00 +7/16 +0.00 delayed 20 mins - disclaimerMonday January 11, 8:00 am Eastern Time Company Press Release SOURCE: TelVue Corporation TelVue Corporation Ready to Deploy Internet PPV Ordering - Files For Patent MT. LAUREL, N.J., Jan. 11 /PRNewswire/ -- TelVue Corporation (OTC Bulletin Board: TEVE - news) announced today that it is in the process of concluding field trials of its Internet Pay Per View (PPV) ordering System. This system allows cable subscribers with access to the Internet to order PPV movies and events and watch them on their cable TV equipped television set. A spokesperson for TelVue also said that TelVue has filed a patent application for that process and several other procedures that allow cable subscribers to control their addressable cable converter using the Internet and their home personal computer. Field trials of the Internet PPV ordering system were begun in October of 1998 and conducted in conjunction with Prevue Networks and Comcast Corporation [Nasdaq:CMCSA - news] on seven northern New Jersey cable systems. According to TelVue's President, Frank Carcione, the trials went well with few, if any, technical hitches. For security purposes, cable subscribers needed to register for the service one time, on an automated basis, using their home telephone. From then on they enter the ''passcode'' they registered over the telephone on the Internet ordering form. Mr. Carcione said, ''Telephone registrations to orders were about four to one. This means that people like the concept and signed up to use the service, even if they did not have a specific movie in mind to order. We also found out that people who had never ordered PPV before did so using the Internet during the test. This is very encouraging because the Internet has the potential to increase PPV business for the cable operator.'' Adelphia Cable is also using Internet PPV ordering on a limited basis for the Tyson vs. Botha fight scheduled for January 16, 1999. Adelphia cable subscribers can order the fight in advance using the Internet. Cable subscribers go to the Adelphia website (http://www.adelphia.net) and then are linked to an order form that connects to TelVue for order processing. According to Joseph Murphy, TelVue's Executive Vice President of Sales, TelVue has a complete Internet website ordering package that can be branded by the cable system and will be available to cable systems starting this week. The package contains web pages that provide for PPV ordering over the Internet, links to PPV schedules and program content websites. Mr. Murphy says, ''Cable subscribers can find out what's on, when it's on, what channel it's on and order it right then and there. The package can be linked to a cable system's existing website or TelVue can host the package for the cable system at ppvorder.com. This means that even if a system does not have a website or its own server, it can still offer its own branded PPV Internet ordering.'' TelVue is a public company and trades as TEVE. SOURCE: TelVue Corporation ------------------------------------------------------------------------ More Quotes and News: •Comcast Corp (Nasdaq:CMCSA - news)•Telvue Corp (OTC BB:TEVE - news) Related News Categories: entertainment, internet

To: Gator who wrote (32229)	1/11/1999 2:14:00 PM
From: DR. MEADE	Read Replies (1) \| Respond to of 34592

More APPI news today, and its important ********* Monday January 11, 12:50 pm Eastern Time Company Press Release SOURCE: Advanced Plant Pharmaceuticals, Inc. Advanced Plant Pharmaceuticals, Inc. - APPI - Announces the Launching of their Patent Pending Immune System Supplement 'ACA' in the United States and International Markets NEW YORK, Jan. 11 /PRNewswire/ -- Advanced Plant Pharmaceuticals Inc. (OTC Bulletin Board: APPI - news) announced today that they have officially launched their patent pending product ACA for retail sales in the United States and Internationally. Advanced Plant Pharmaceuticals, Inc. has officially launched the nutritional version of Abavca. ACA the standardized pharmaceutical grade nutritional product is targeted for the CFS (Chronic Fatigue Syndrome) and Immune Supplement market. ACA has been proven to strengthen the immune system as well as fight the spread of HIV virus. This is an orally ingested compound that in Pilot studies, Case studies and in In-vitro studies in the USA and other countries has demonstrated reversal of glandular swelling, restoration of well-being and associated weight gain, improvement in response to skin hypersensitivity tests, increase in the circulating concentration of helper T cells (CD4-positive cells); associated with this is an improvement in the CD4/CD8 ratio, with many patients returning to a normal ratio. This type of response is far different from those experienced by users of any one drug regimen currently on the market. People who have access to the expensive new class of drugs called protease inhibitors have seen similar responses when used in combination with AZT or one of the older products, but they are not effective for all people. The struggle for appropriate medication is all the more difficult because scientists and physicians do not have a clear understanding of which drugs work best together and whether a patient will prove to be resistant to any of the drugs in the combination therapy now in use. Also, approximately 100,000 patients have access to these treatments out of an estimated population of 21.8 million people worldwide who are infected. The CFS and Immune markets are estimated to be in excess of 6 billion dollars annually. The total nutritional supplement market is estimated to be in excess of 23 billion dollars annually in the USA. Prior distribution agreements signed with Klien Associates of Israel and Maxwell Associates of England include the distribution of ACA. Both Companies believe that this product will have immediate market acceptance. APPI will seek distribution partners who are capable of gaining access to the areas of the world with the most patients, India, Southeast Asia and Africa specifically. ACA will be available on the Company web site located at advancedplantpharm.com within the week. On the pharmaceutical side APPI has an approved IND for a Phase I/II clinical trial for the use of Abavca in the treatment of AIDS. This trial is anticipated to begin enrolling patients in the 3rd quarter of 1999, following the completion of further regulatory studies, which will be completed in March. This study should last about 9 months and results should be submitted to the FDA within one year from its commencement. The company expects to announce further agreements in the near future. APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Lo-Chol in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. SOURCE: Advanced Plant Pharmaceuticals, Inc. ------------------------------------------------------------------------ More Quotes and News:Advanced Plant Pharmaceuticals Inc (OTC BB:APPI - news)Related News Categories: medical/pharmaceutical ------------------------------------------------------------------------ Help ------------------------------------------------------------------------ Copyright © 1999 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information